Scotland 2021 | Diabetes on the Net

Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Diabetes care:
The shape of things to come

Book your place for our upcoming virtual conference

Tuesday 26 October 2021

The Primary Care Diabetes Society (PCDS)

14th annual Scottish Conference

Organised by the PCDS, the only association solely committed to the needs of primary care diabetes, this virtual conference will examine diabetes care from a Scottish perspective. This year, the 14th for the event, we will celebrate the heritage of this event by doing what we do best: exploring a range of issues that impact the most on day-to-day diabetes care delivery in Scotland. And we will be doing so in a virtual format.

As the Scottish representatives of the PCDS Committee, we are delighted to be delivering this invaluable opportunity for us all to come together, virtually, and discuss the real core issues in Scottish diabetes care delivery.

We look forward to welcoming you to the virtual conference.

Scottish Representatives on the PCDS Committee

This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more

  • Ask the experts your burning questions through the LIVE Q&A at the end of each session
  • Log on anytime during the day from the comfort of your own home to view the sessions ​
  • Don’t worry if you miss something, all of the content will be available on-demand 
  • Claim 5 CPD points for the full day virtual conference



Chair’s introduction



  • Using some data from previous presentation
  • New evidence about COVID in diabetes
  • New treatments and vaccination
  • Lessons learned about COVID in people with diabetes

15 min break



15 min break


Fatty liver disease

  • Cardiovascular and renal disease, the relationship with diabetes
  • Additional factors, hypertension, dyslipidemia and insulin resistance
  • New medications and guidance

15 min break


‘In Practice’ masterclasses | Rotation 1

1. A pot-pourri of diabetes

2. Pre-diabetes

3. Renal

4. 'In association' masterclass

15 min break


‘In Practice’ masterclasses | Rotation 2

1. A pot-pourri of diabetes

2. Pre-diabetes

3. Renal

15 min break


To low carb or not to low carb?

15 min break



15 min break


Diabetes Distilled


Chair’s concluding remarks



Kashif Ali

GP Partner, Ayr


Pam Brown

GP, Swansea


Kevin Fernando

GPwSI in Diabetes and Medical Education, North Berwick


Nicola Guess


Lyndsey McConnell

GPwSI in Diabetes, Kinlochleven


Paul Newman

GP, Glasgow


Abd Tahrani

Research Training Fellow and Clinical Lecturer in Diabetes and Endocrinology, Birmingham

Conference sponsors



AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit


Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded in 1876 by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission.

To learn more, visit


Abbott’s diabetes care division

At Abbott, we believe people with diabetes should have the freedom to enjoy a full, active life. That’s why we’re focused on making breakthrough technology accessible and approachable for all. Our groundbreaking sensing technology is revolutionising how people monitor their glucose and providing healthcare teams with more data to drive better informed treatment decisions.


AgaMatrix Europe Ltd.

The WaveSense JAZZtest strip has been a popular choice for CCGs, Health Boards and HCPs for many years, resulting in it being the 2nd most prescribed test strip in the UK.  AgaMatrix have worked hard to secure this position by offering high quality, accurate blood glucose testing combined with second-to-none support.

The WaveSense JAZZtest strip is used in all three WaveSense JAZZ blood glucose monitoring systems including the increasingly popular WaveSense JAZZWIRELESS blood glucose meter which enables remote management of patients.

Find out more about more about how AgaMatrix can support your practice with the implementation of AgaMatrix Clinic Review Service.  This free of charge service assists GP practices to optimise blood glucose prescribing and is fully managed from beginning to end by the AgaMatrix pharmacy team under the control of the GP surgery throughout the process.  A remote version of the service is now available.

Novo Nordisk

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs. Headquartered in Denmark, Novo Nordisk employs approximately 45,000 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products. For more information visit

Taking place on:

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.